We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Plasma-derived medicines company Grifols has executed purchase arrangements with South Korean-based GC Pharma to acquire a plasma fractionation facility in Montreal, Canada for $460m.